Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
Abstract Despite many improvements in its prevention and management, acute coronary syndrome (ACS) remains a major cause of morbidity and mortality in the developed world. Lipid management is an important part of secondary prevention after ACS, but many patients currently remain undertreated and do...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-12-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.018897 |
| _version_ | 1828888554602758144 |
|---|---|
| author | Bimmer E. Claessen Paul Guedeney C. Michael Gibson Dominick J. Angiolillo Davide Cao Norman Lepor Roxana Mehran |
| author_facet | Bimmer E. Claessen Paul Guedeney C. Michael Gibson Dominick J. Angiolillo Davide Cao Norman Lepor Roxana Mehran |
| author_sort | Bimmer E. Claessen |
| collection | DOAJ |
| description | Abstract Despite many improvements in its prevention and management, acute coronary syndrome (ACS) remains a major cause of morbidity and mortality in the developed world. Lipid management is an important part of secondary prevention after ACS, but many patients currently remain undertreated and do not attain guideline‐recommended levels of low‐density lipoprotein cholesterol reduction. This review details the current state of evidence on lipid management in patients presenting with ACS, provides directions for identification of patients who may benefit from early escalation of lipid‐lowering therapy, and discusses novel lipid‐lowering medication that is currently under investigation in clinical trials. Moreover, a treatment algorithm aimed at attaining guideline‐recommended low‐density lipoprotein cholesterol levels is proposed. Despite important advances in the initial treatment and secondary prevention of ACS, ≈20% of ACS survivors experience a subsequent ischemic cardiovascular event within 24 months, and 5‐year mortality ranges from 19% to 22%. Knowledge of the current state of evidence‐based lipid management after ACS is of paramount importance to improve outcomes after ACS. |
| first_indexed | 2024-12-13T12:25:27Z |
| format | Article |
| id | doaj.art-e755680436b845f0b7d60fda07572c5d |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-12-13T12:25:27Z |
| publishDate | 2020-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-e755680436b845f0b7d60fda07572c5d2022-12-21T23:46:23ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802020-12-0192410.1161/JAHA.120.018897Lipid Management in Patients Presenting With Acute Coronary Syndromes: A ReviewBimmer E. Claessen0Paul Guedeney1C. Michael Gibson2Dominick J. Angiolillo3Davide Cao4Norman Lepor5Roxana Mehran6The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NYThe Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NYBeth Israel Deaconess Medical Center New York NYDivision of Cardiology University of Florida College of Medicine Jacksonville FLThe Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NYCedars‐Sinai Heart InstituteGeffen School of Medicine‐University of Califonia ‐ Los Angeles Los Angeles CAThe Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NYAbstract Despite many improvements in its prevention and management, acute coronary syndrome (ACS) remains a major cause of morbidity and mortality in the developed world. Lipid management is an important part of secondary prevention after ACS, but many patients currently remain undertreated and do not attain guideline‐recommended levels of low‐density lipoprotein cholesterol reduction. This review details the current state of evidence on lipid management in patients presenting with ACS, provides directions for identification of patients who may benefit from early escalation of lipid‐lowering therapy, and discusses novel lipid‐lowering medication that is currently under investigation in clinical trials. Moreover, a treatment algorithm aimed at attaining guideline‐recommended low‐density lipoprotein cholesterol levels is proposed. Despite important advances in the initial treatment and secondary prevention of ACS, ≈20% of ACS survivors experience a subsequent ischemic cardiovascular event within 24 months, and 5‐year mortality ranges from 19% to 22%. Knowledge of the current state of evidence‐based lipid management after ACS is of paramount importance to improve outcomes after ACS.https://www.ahajournals.org/doi/10.1161/JAHA.120.018897acute coronary syndromecardiovascularlipids |
| spellingShingle | Bimmer E. Claessen Paul Guedeney C. Michael Gibson Dominick J. Angiolillo Davide Cao Norman Lepor Roxana Mehran Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease acute coronary syndrome cardiovascular lipids |
| title | Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review |
| title_full | Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review |
| title_fullStr | Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review |
| title_full_unstemmed | Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review |
| title_short | Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review |
| title_sort | lipid management in patients presenting with acute coronary syndromes a review |
| topic | acute coronary syndrome cardiovascular lipids |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.120.018897 |
| work_keys_str_mv | AT bimmereclaessen lipidmanagementinpatientspresentingwithacutecoronarysyndromesareview AT paulguedeney lipidmanagementinpatientspresentingwithacutecoronarysyndromesareview AT cmichaelgibson lipidmanagementinpatientspresentingwithacutecoronarysyndromesareview AT dominickjangiolillo lipidmanagementinpatientspresentingwithacutecoronarysyndromesareview AT davidecao lipidmanagementinpatientspresentingwithacutecoronarysyndromesareview AT normanlepor lipidmanagementinpatientspresentingwithacutecoronarysyndromesareview AT roxanamehran lipidmanagementinpatientspresentingwithacutecoronarysyndromesareview |